• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Concord Medical Services Holdings Limited

    4/20/23 7:14:06 AM ET
    $CCM
    Medical/Nursing Services
    Health Care
    Get the next $CCM alert in real time by email
    6-K 1 tm2313314d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of April 2023

     

     

     

    Commission File Number: 001-34563

     

     

     

    CONCORD MEDICAL SERVICES HOLDINGS LIMITED

     

     

     

    Room 2701-05, Tower A, Global Trade Center

    36 North Third Ring Road East, Dongcheng District

    Beijing 100013

    People’s Republic of China

    (Address of principal executive office)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F        x                 Form 40-F          ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

     

     

     

     

    Supplemental Submission Pursuant to Item 16I(a) of Form 20-F

     

    Concord Medical Services Holdings Limited (the “Company”) is submitting to the U.S. Securities and Exchange Commission (the “SEC”) the following information as required under Item 16I(a) of Form 20-F in relation to the Holding Foreign Companies Accountable Act, as amended (the “HFCAA”).

     

    On May 26, 2022, the Company was conclusively identified by the SEC as a Commission-Identified Issuer pursuant to the HFCAA because it filed an annual report on Form 20-F for the year ended December 31, 2021 with the SEC on April 29, 2022 with an audit report issued by Shandong Haoxin Certified Accountants Co., Ltd., a registered public accounting firm retained by the Company for the preparation of the audit report on the Company’s financial statements included therein. Shandong Haoxin Certified Accountants Co., Ltd. is a registered public accounting firm headquartered in mainland China, a jurisdiction where the Public Company Accounting Oversight Board (the “PCAOB”) determined that it was unable to inspect or investigate completely registered public accounting firms headquartered there until December 2022 when the PCAOB vacated its previous determination. In response to Item 16I(a) of Form 20-F, the Company believes that the following information establishes that it is not owned or controlled by a governmental entity in mainland China.

     

    To the Company’s knowledge based on its register of members and public EDGAR filings made by its shareholders, no shareholder other than Morgancreek Investment Holdings Limited (“Morgancreek”), Solar Honor Limited (“Solar Honor”), Oasis Inspire Limited (“Oasis Inspire”) and Bluestone Holdings Limited (“Bluestone”) owned 5.0% or more of the Company’s outstanding shares as of December 31, 2022.

     

    ·Morgancreek beneficially owned Class A and Class B ordinary shares, representing 40.1% of the Company’s outstanding shares (or 73.2% of the Company’s total voting power) as of December 31, 2022. Morgancreek is a limited liability company organized under the laws of the British Virgin Islands. Cherrylane Investments Limited, a limited liability company organized under the laws of the British Virgin Islands indirectly wholly owned by Ms. Bi Zhang, the spouse of Dr. Jianyu Yang, the Company’s chief executive officer and chairman of the board of directors, holds 70% of the equity interests in Morgancreek. Model Oasis Limited, a limited liability company organized under the laws of the British Virgin Islands wholly owned by Ms. Sirong Tian, indirectly holds 30% of the equity interests in Morgancreek. Dr. Yang is the sole director of Morgancreek and has the power to direct Morgancreek as to the voting and disposition of the shares held by Morgancreek. Dr. Yang may be deemed the beneficial owner of all the shares held by Morgancreek.

     

    ·Solar Honor beneficially owned Class A ordinary shares, representing 11.8% of the Company’s outstanding shares (or 2.8% of the Company’s total voting power) as of December 31, 2022. Solar Honor is a limited liability company organized under the laws of British Virgin Islands wholly owned by Ms. Sirong Tian.

     

    ·Oasis Inspire beneficially owned Class A ordinary shares, representing 10.0% of the Company’s outstanding shares (or 2.4% of the Company’s total voting power) as of December 31, 2022. Oasis Inspire is a limited liability company organized under the laws of British Virgin Islands directly wholly owned by Fosun Industrial Holdings Limited which is wholly owned by Fosun International Limited, as reported in the Amendment No. 1 to Schedule 13D dated January 16, 2019.

     

    ·Bluestone beneficially owned Class B ordinary shares, representing 5.8% of the Company’s outstanding shares (or 13.8% of the Company’s total voting power) as of December 31, 2022. Bluestone is a limited liability company organized under the laws of the British Virgin Islands, of which Mr. Zheng Cheng, the Company’s director, is a sole director and sole shareholder.

     

     

    Please refer to “Item 6. Directors, Senior Management and Employees—E. Share Ownership” of the Company’s annual report on Form 20-F for the year ended December 31, 2022 filed with the SEC on April 19, 2023 for more details.

     

    In addition, the Company is not aware of any governmental entity in mainland China that is in possession of the power, direct or indirect, to direct or cause the direction of the management and policies of the Company, whether through the ownership of voting securities, by contract, or otherwise.

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      CONCORD MEDICAL SERVICES HOLDINGS LIMITED
         
      By: /s/ Jianyu Yang
      Name: Jianyu Yang
      Title: Chairman and Chief Executive Officer

     

    Date: April 20, 2023

     

     

    Get the next $CCM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CCM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Concord Medical Schedules 2025 Annual Meeting of Shareholders

    BEIJING, Dec. 2, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it will hold its 2025 annual general meeting of shareholders (the "Meeting") on December 29, 2025, at 10:00 a.m. (Beijing Time). The meeting will be held at Room 26A1-26A5, East Tower, Hanwei Building, No. 7 Guanghua Road, Chaoyang District, Beijing, China. The shareholder record date is December 19, 2025. A copy of the notice of Meeting is available on the Company's investor relations website at https://ir.ccm.cn.  No proposal will be submitted

    12/2/25 7:00:00 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    Concord Medical Reports Financial Results for the First Half of 2025

    BEIJING, Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2025[1]. 2025 First Half Highlights Total net revenues were RMB200.6 million (US$28.0 million) in the first half of 2025, representing a 8.3% decrease from total net revenues of RMB218.8 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB153.0 million (US$21.4 million) and the net revenues from the network

    9/26/25 7:30:00 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    Concord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant Melanoma

    BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare, successfully completed the first proton therapy treatment in China for a patient with choroidal malignant melanoma. Choroidal malignant melanoma is a common intraocular malignancy. The traditional standard treatment is enucleation, i.e. eye removal. Although enucleation can effect

    7/14/25 4:05:00 PM ET
    $CCM
    Medical/Nursing Services
    Health Care

    $CCM
    SEC Filings

    View All

    SEC Form 6-K filed by Concord Medical Services Holdings Limited

    6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)

    12/2/25 7:18:17 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    SEC Form 6-K filed by Concord Medical Services Holdings Limited

    6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)

    9/30/25 6:02:41 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    SEC Form 6-K filed by Concord Medical Services Holdings Limited

    6-K - Concord Medical Services Holdings Ltd (0001472072) (Filer)

    9/26/25 7:35:08 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    $CCM
    Financials

    Live finance-specific insights

    View All

    Concord Medical Reports Financial Results for the First Half of 2025

    BEIJING, Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2025[1]. 2025 First Half Highlights Total net revenues were RMB200.6 million (US$28.0 million) in the first half of 2025, representing a 8.3% decrease from total net revenues of RMB218.8 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB153.0 million (US$21.4 million) and the net revenues from the network

    9/26/25 7:30:00 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    Concord Medical Reports Financial Results for the First Half of 2024

    BEIJING, Sept. 27, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2024[1]. 2024 First Half Highlights Total net revenues were RMB218.8 million (US$30.1 million) in the first half of 2024, representing a 23.1% decrease from total net revenues of RMB284.5 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB137.8 million (US$19.0 million) and the net revenues from the network

    9/27/24 7:00:00 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    Concord Medical Reports Financial Results for the First Half of 2023

    BEIJING, Sept. 22, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE:CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2023[1]. 2023 First Half Highlights Total net revenues were RMB284.5 million (US$39.2 million) in the first half of 2023, representing a 97.2% increase from total net revenues of RMB144.3 million in the same period last year. Total net rev

    9/22/23 5:00:00 PM ET
    $CCM
    Medical/Nursing Services
    Health Care

    $CCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - Concord Medical Services Holdings Ltd (0001472072) (Subject)

    2/16/21 7:12:46 AM ET
    $CCM
    Medical/Nursing Services
    Health Care

    $CCM
    Leadership Updates

    Live Leadership Updates

    View All

    Concord Medical Announces Divestment of Singapore Concord International Hospital

    BEIJING, Dec. 28, 2020 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that the Company has, through its subsidiaries, entered into a definitive agreement to sell 90% equity interest in Concord Healthcare Singapore Pte Ltd, which operates and owns a general medical and surgical hospital, namely Concord International Hospital ("CIH"), for a total consideration of approximately SG$52.2 million. The p

    12/28/20 6:47:00 AM ET
    $CCM
    Medical/Nursing Services
    Health Care